CN102309464A - 一种叶酸片及其制备方法 - Google Patents
一种叶酸片及其制备方法 Download PDFInfo
- Publication number
- CN102309464A CN102309464A CN 201110280578 CN201110280578A CN102309464A CN 102309464 A CN102309464 A CN 102309464A CN 201110280578 CN201110280578 CN 201110280578 CN 201110280578 A CN201110280578 A CN 201110280578A CN 102309464 A CN102309464 A CN 102309464A
- Authority
- CN
- China
- Prior art keywords
- parts
- folic acid
- weight
- starch
- lactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims abstract description 101
- 235000019152 folic acid Nutrition 0.000 title claims abstract description 55
- 239000011724 folic acid Substances 0.000 title claims abstract description 55
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 229960000304 folic acid Drugs 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title abstract description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 34
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 24
- 229920002472 Starch Polymers 0.000 claims abstract description 24
- 229930006000 Sucrose Natural products 0.000 claims abstract description 24
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 24
- 239000008101 lactose Substances 0.000 claims abstract description 24
- 235000019698 starch Nutrition 0.000 claims abstract description 24
- 239000008107 starch Substances 0.000 claims abstract description 24
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims description 23
- 239000005720 sucrose Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000007779 soft material Substances 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 10
- 229940014144 folate Drugs 0.000 claims description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- 238000004090 dissolution Methods 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 7
- 238000005516 engineering process Methods 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 229960004793 sucrose Drugs 0.000 abstract 1
- 239000000047 product Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 6
- 239000013558 reference substance Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 206010009259 cleft lip Diseases 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 201000010193 neural tube defect Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- -1 purine nucleic acid Chemical class 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
样品来源 | 实验组1 | 实验组2 | 实验组3 | 实验组4 | 实验组5 | 对照组 |
1 | 101.3% | 97.40% | 101.40% | 97.80% | 101.30% | 95.00% |
2 | 101.8% | 99.10% | 99.40% | 99.60% | 99.70% | 105.30% |
3 | 100.0% | 101.30% | 97.60% | 103.20% | 98.60% | 103.80% |
4 | 98.5% | 102.40% | 98.30% | 102.10% | 99.30% | 104.50% |
5 | 98.8% | 100.30% | 98.80% | 98.70% | 102.60% | 93.80% |
6 | 101.3% | 99.50% | 101.20% | 99.40% | 96.70% | 105.30% |
7 | 100.3% | 96.90% | 102.10% | 96.90% | 97.60% | 104.30% |
8 | 102.0% | 99.70% | 103.40% | 97.50% | 98.40% | 92.80% |
9 | 97.6% | 101.40% | 97.90% | 98.60% | 99.10% | 105.50% |
10 | 100.0% | 99.70% | 99.70% | 98.30% | 101.20% | 104.00% |
A+1.80S | 2.1 | 3.32 | 3.53 | 4.4 | 3.8 | 8.0 |
样品来源 | 实验组1 | 实验组2 | 实验组3 | 实验组4 | 实验组5 | 对照组 |
1 | 101.3 | 101.7 | 100 | 107.1 | 97.5 | 92.4 |
2 | 107.1 | 98.6 | 101.5 | 101 | 102.1 | 93.0 |
3 | 99 | 102 | 103 | 103.7 | 97.5 | 93.6 |
4 | 104 | 100.5 | 96.5 | 100.2 | 99.4 | 93.5 |
5 | 15.9 | 99.0 | 103.4 | 100.2 | 99.0 | 93.4 |
6 | 100.6 | 96.7 | 104.2 | 105.2 | 103.2 | 93.5 |
平均值 | 103 | 100 | 101 | 103 | 100 | 93.2 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110280578 CN102309464B (zh) | 2011-09-21 | 2011-09-21 | 一种叶酸片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110280578 CN102309464B (zh) | 2011-09-21 | 2011-09-21 | 一种叶酸片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102309464A true CN102309464A (zh) | 2012-01-11 |
CN102309464B CN102309464B (zh) | 2013-04-24 |
Family
ID=45423287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110280578 Active CN102309464B (zh) | 2011-09-21 | 2011-09-21 | 一种叶酸片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102309464B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102861020A (zh) * | 2012-09-25 | 2013-01-09 | 上海交通大学医学院附属仁济医院 | 叶酸在制备预防大肠腺瘤初发药物中的应用 |
CN103070831A (zh) * | 2013-02-02 | 2013-05-01 | 常州市新鸿医药化工技术有限公司 | 10~90%叶酸颗粒制备方法 |
CN104434839A (zh) * | 2014-12-05 | 2015-03-25 | 海南卫康制药(潜山)有限公司 | 一种叶酸组合物冻干片及其制备方法 |
CN106038620A (zh) * | 2016-07-11 | 2016-10-26 | 山西普德药业有限公司 | 一种银杏叶片的制备方法 |
CN112190559A (zh) * | 2020-11-06 | 2021-01-08 | 北京斯利安药业有限公司 | 一种控制释放的叶酸片及其制备方法 |
CN113855641A (zh) * | 2021-11-22 | 2021-12-31 | 天津力生制药股份有限公司 | 一种叶酸固体制剂的制备方法 |
CN114404375A (zh) * | 2022-01-21 | 2022-04-29 | 武汉九珑人福药业有限责任公司 | 一种叶酸固体制剂及其原料组合物、制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1186664A (zh) * | 1997-11-13 | 1998-07-08 | 北京医科大学实验药厂 | 用于预防神经管畸形的叶酸增补剂 |
US20020052374A1 (en) * | 2000-06-07 | 2002-05-02 | Rabelink Ton J. | Pharmaceutical preparation containing at least folic acid or a folate and tetrahydrobiopterin (bh4) or derivatives thereof used for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase (nos) |
CN101642425A (zh) * | 2008-08-04 | 2010-02-10 | 北京瑞伊人科技发展有限公司 | 叶酸肠溶制剂组合物及其制备方法 |
CN101862333A (zh) * | 2009-04-20 | 2010-10-20 | 天津药物研究院 | 左亚叶酸钠稳定的口服制剂及其制备方法 |
-
2011
- 2011-09-21 CN CN 201110280578 patent/CN102309464B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1186664A (zh) * | 1997-11-13 | 1998-07-08 | 北京医科大学实验药厂 | 用于预防神经管畸形的叶酸增补剂 |
US20020052374A1 (en) * | 2000-06-07 | 2002-05-02 | Rabelink Ton J. | Pharmaceutical preparation containing at least folic acid or a folate and tetrahydrobiopterin (bh4) or derivatives thereof used for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase (nos) |
CN101642425A (zh) * | 2008-08-04 | 2010-02-10 | 北京瑞伊人科技发展有限公司 | 叶酸肠溶制剂组合物及其制备方法 |
CN101862333A (zh) * | 2009-04-20 | 2010-10-20 | 天津药物研究院 | 左亚叶酸钠稳定的口服制剂及其制备方法 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102861020A (zh) * | 2012-09-25 | 2013-01-09 | 上海交通大学医学院附属仁济医院 | 叶酸在制备预防大肠腺瘤初发药物中的应用 |
CN103070831A (zh) * | 2013-02-02 | 2013-05-01 | 常州市新鸿医药化工技术有限公司 | 10~90%叶酸颗粒制备方法 |
CN104434839A (zh) * | 2014-12-05 | 2015-03-25 | 海南卫康制药(潜山)有限公司 | 一种叶酸组合物冻干片及其制备方法 |
CN106038620A (zh) * | 2016-07-11 | 2016-10-26 | 山西普德药业有限公司 | 一种银杏叶片的制备方法 |
CN106038620B (zh) * | 2016-07-11 | 2019-09-17 | 山西普德药业有限公司 | 一种银杏叶片的制备方法 |
CN112190559A (zh) * | 2020-11-06 | 2021-01-08 | 北京斯利安药业有限公司 | 一种控制释放的叶酸片及其制备方法 |
CN112190559B (zh) * | 2020-11-06 | 2022-02-11 | 北京斯利安药业有限公司 | 一种控制释放的叶酸片及其制备方法 |
CN113855641A (zh) * | 2021-11-22 | 2021-12-31 | 天津力生制药股份有限公司 | 一种叶酸固体制剂的制备方法 |
CN114404375A (zh) * | 2022-01-21 | 2022-04-29 | 武汉九珑人福药业有限责任公司 | 一种叶酸固体制剂及其原料组合物、制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102309464B (zh) | 2013-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102309464B (zh) | 一种叶酸片及其制备方法 | |
CN102266307B (zh) | 一种缬沙坦胶囊及其制备方法 | |
CN102091048A (zh) | 盐酸阿比朵尔片的制备方法及其质量控制方法 | |
CN103784411B (zh) | 一种盐酸厄洛替尼药用组合物及其制备方法 | |
CN103462918B (zh) | 一种盐酸伐昔洛韦片剂及其制备方法 | |
CN104351473A (zh) | 一种用于畜禽的水溶性复合维生素微丸的制备方法 | |
CN104224831A (zh) | 一种叶酸类营养补充剂的制备方法 | |
CN105535018B (zh) | 一种碳酸钙d3颗粒及其制备方法 | |
CN103142487A (zh) | 一种高含量妥曲珠利可溶性粉剂及其制备方法和应用 | |
CN103919747A (zh) | 一种安立生坦片剂组合物及其制备方法 | |
CN103637994A (zh) | 一种预混辅料及其制备工艺 | |
CN105395506B (zh) | 一种盐酸可乐定缓释片 | |
CN106511288A (zh) | 一种非布司他片剂的制备方法 | |
CN106924192B (zh) | 一种中药颗粒剂及其制备方法 | |
CN104887638A (zh) | 一种吉非替尼片剂的制备方法 | |
CN102499922B (zh) | 一种注射用盐酸头孢甲肟组合物及其制剂 | |
CN106265557A (zh) | 含有替格瑞洛的药物组合物 | |
CN102885774B (zh) | 普拉格雷组合物及其制备方法 | |
CN105168169A (zh) | 一种吉非替尼片剂及其制备方法 | |
CN117045608A (zh) | 一种维生素b2的速释制剂及制备方法 | |
CN105168165B (zh) | 一种盐酸乐卡地平片及其制备方法 | |
CN105193760A (zh) | 一种高含量硫酸氨基葡萄糖片及制备方法 | |
CN104138365A (zh) | 一种替米沙坦胶囊剂及其制备方法 | |
CN103191057A (zh) | 头孢噻呋的水性悬浮注射液及其制备方法 | |
CN103142500B (zh) | 一种依托泊苷缓释颗粒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: LIAONING GELIN BIOLOGICAL PHARMACEUTICAL GROUP CO. Free format text: FORMER OWNER: SHENYANG GELIN PHARMACEUTICAL CO., LTD. Effective date: 20141104 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20141104 Address after: Shen North Road Shenbei New Area Huishan Economic Development Zone of Shenyang city of Liaoning Province, No. 176 110164 Patentee after: LIAONING GREEN BIO-PHARMACEUTICAL GROUP Co.,Ltd. Address before: Shen North Road Shenbei New Area Huishan Economic Development Zone of Shenyang city of Liaoning Province, No. 176 110164 Patentee before: Shenyang Green Pharmaceutical Co.,Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Shen North Road Shenbei New Area Huishan Economic Development Zone of Shenyang city of Liaoning Province, No. 176 110164 Patentee after: LIAONING GREEN BIOLOGICAL PHARMACEUTICAL GROUP Co.,Ltd. Address before: Shen North Road Shenbei New Area Huishan Economic Development Zone of Shenyang city of Liaoning Province, No. 176 110164 Patentee before: LIAONING GREEN BIO-PHARMACEUTICAL GROUP Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Shen North Road Shenbei New Area Huishan Economic Development Zone of Shenyang city of Liaoning Province, No. 176 110164 Patentee after: Yuanyan Yaogang Biopharmaceutical (Shenyang) Co.,Ltd. Address before: Shen North Road Shenbei New Area Huishan Economic Development Zone of Shenyang city of Liaoning Province, No. 176 110164 Patentee before: Yuanyan Pharmaceutical Port Bioindustry (Liaoning) Group Co.,Ltd. Address after: Shen North Road Shenbei New Area Huishan Economic Development Zone of Shenyang city of Liaoning Province, No. 176 110164 Patentee after: Yuanyan Pharmaceutical Port Bioindustry (Liaoning) Group Co.,Ltd. Address before: Shen North Road Shenbei New Area Huishan Economic Development Zone of Shenyang city of Liaoning Province, No. 176 110164 Patentee before: LIAONING GREEN BIOLOGICAL PHARMACEUTICAL GROUP Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |